Sandoz stock gains focus as Brazil semaglutide launch begins

Published on 11/09/2026 at 11:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sandoz stock is in focus after the company launched its first semaglutide treatment in Brazil. The product targets adults with type-2 diabetes.

Brazil launch advances GLP-1 strategy

Sandoz launched Owozy in Brazil through local partner Biolab & Co.
The treatment was approved for type-2 diabetes on July 29, 2026.
Sandoz expects no material financial contribution from the launch this year.

Sandoz, CH1243598427, Illustration mit AI erstellt.

Sandoz announced on Monday, November 9, 2026, that it has launched Owozy, a semaglutide solution for injection, in Brazil. The company said the product expands access to a new treatment option in one of the world's largest and fastest-growing GLP-1 markets. The announcement was published by Sandoz in an ad hoc release under the SIX Swiss Exchange Listing Rules.

Owozy was developed by Adalvo and received approval from Brazil's Agência Nacional de Vigilância Sanitária on July 29, 2026, for adults with type-2 diabetes. Sandoz is commercializing the product through local partner Biolab & Co under a distribution and promotion agreement signed earlier this year. The treatment is supplied in a pre-filled, multi-dose disposable pen.

Market access and product positioning

Sandoz said the Brazilian GLP-1 market is worth an estimated 2.7 billion US dollars. More than 16.5 million adults in Brazil live with diabetes, according to the company release, while more than five million people are estimated to remain undiagnosed. Those figures underline the potential patient pool, although access, competition and reimbursement conditions will determine how quickly the launch develops commercially.

Owozy contains semaglutide at a concentration of 1.34 milligrams per milliliter and is administered once weekly in accordance with approved product information and medical advice. Approved presentations include 1.5 milliliter and 3.0 milliliter pre-filled pens. The medicine is intended for adults whose type-2 diabetes is insufficiently controlled, alongside diet and exercise.

Financial impact remains limited initially

Chief Executive Officer Richard Saynor described the launch as a milestone for Sandoz and said it supports the company's ambition to become a leading generic GLP-1 player. The company also linked the Brazilian launch to the GLP-1 strategy presented at its September 2026 Capital Markets Day, which included early launches in Brazil and Canada.

Sandoz nevertheless expects no material financial contribution from the semaglutide launch this year. For investors, the announcement therefore adds a strategic growth option rather than an immediate earnings driver. The next commercial milestones will be prescription uptake, distribution performance and the planned expansion of the GLP-1 portfolio.

Sandoz stock traded at 92.97 euros on Lang & Schwarz at 11:01 CET on Monday, November 9, 2026, 0.08 percent below the Xetra close of 93.04 euros on Friday, November 6, according to Yahoo Finance. Investors can follow the real-time quote of Sandoz stock for subsequent trading updates.